QSAM Biosciences, Inc. (OTCQB: QSAM) @ 01/11/2022

Friday, January 21st, 2022 @ 8:04PM

Next Generation Nuclear Technology Focused on the Eradication of Bone Cancer

Management believes its initial technology, CycloSam® has a strong pathway to commercialization in a Global Market that is valued at $12.6 Billion*

Company Summary:

QSAM Biosciences, Inc. (OTCQB: QSAM), is developing next generation nuclear medicines for the treatment of cancer and related diseases and conditions.

QSAM’s initial technology is Samarium-153 DOTMP, aka CycloSam^®, a clinical-staged bone targeting radiopharmaceutical developed by IsoTherapeutics Group LLC, leaders in the nuclear medicine space.

CycloSam^® is cleared by the FDA under an investigator initiated IND to commence human dosing immediately in patients with osteosarcoma and bone metastasis.

CycloSam^® was also cleared by FDA and successfully used under a single-patient IND to perform bone marrow ablation prior to allogenic marrow transplantation (BMA/T) in 2020.

Key Metrics @ 01/11/2022

Closing Price: $0.19	$0.19
52 Week Range: $0.15 to $1.09	$0.15 to $1.09
Shares Outstanding: 66.17M	66.17M
Shares in the Float: 11.32M	11.32M
Held @ DTC (01/11/2022): 10.13M	10.13M
Shares Authorized:300M	300M
Average Daily Volume: (30 day): 20.9k	20.9k
Market Cap: $11.60M	$11.60M
Reporting Status: SEC Reporting	SEC Reporting
Financials: Audited	Audited
Most Recent Filing: 10-Q for 09/30/2021 Filed 11/15/21	Filed: 11/15/2021
Fiscal Year-end: 12/31	12/31

(Source: OTC Markets, Yahoo Finance, SEC filings)

Corporate News:

QSAM Biosciences Activates Clinical Sites and Opens Enrollment for its Phase 1 Clinical Trial of CycloSam® for the Treatment of Bone Cancer

Austin, TX, Dec. 01, 2021 (GLOBE NEWSWIRE) — QSAM Biosciences, Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam^®), for the treatment of cancer and related diseases, today announces the activation of its first clinical trial site and the initiation of enrollment of patients into its Phase 1 clinical trial evaluating CycloSam^® for multiple types of bone cancer that either originated in or has metastasized to the bone.

The Company’s initial enrollment site is at Oncology Consultants in Houston, TX.

Click on above link to read the rest of the story

QSAM Biosciences Announces FDA Clearance of IND for Samarium-153 DOTMP (CycloSam®), an Investigational Radiopharmaceutical for the Treatment of Bone Cancer

Austin, TX, Aug. 25, 2021 (GLOBE NEWSWIRE) — QSAM Biosciences, Inc.(OTCQB: QSAM), a company developing next generation nuclear medicines, including Samarium-153 DOTMP (CycloSam^®), for the treatment of cancer and related diseases and conditions, announced that the U.S. Food and Drug Administration (FDA) has cleared QSAM’s investigational new drug (IND) application which allows the Company to commence Phase 1 clinical trials and the dosing of patients with bone cancer.

“This IND clearance is another major milestone for QSAM and the advancement of CycloSam. We expect to commence our Phase 1 open-label dose escalation trial in bone cancer patients by the end of this year.

Click on above link to read the rest of the story

Key Investment Considerations:

Management: “You will not find a management team of this caliber in any other small cap company with a $12 million market cap.” (OTC Stock Review)

CycloSam® has already demonstrated safety and efficacy in animal studies and a human trial performed at the prestigious Cleveland Clinic and is cleared by the FDA under an investigator IND to commence human dosing immediately in patients with osteosarcoma and bone metastasis.

Initial research has identified four initial potential indications for CycloSam®: Osteosarcoma (bone cancer); Metastatic Bone Cancers; Bone Marrow Ablation (removal); Lower Dose Radiation.

Executive Leadership and Advisory Team has extensive domain as well as FDA application/approval process experience.

QSAM shares are significantly undervalued compared to other companies in the FDA approval process. (Penny Stocks News)

Bottom Line Observation:

QSAM is trading close to its 52-week low so this could be a ground floor opportunity for bio-tech/bio-science investors looking for a stock with the potential for a high upward movement in share price.

Interested investors definitely want to keep QSAM on their radar screens or even start building a position in the shares at what appears to be a nice entry point.

______________________________________________________________________

More about QSAM Biosciences, Inc. (OTCQB: QSAM)

QSAM Biosciences, Inc. (f/k/a) Q2Earth, Inc.) is developing next generation nuclear medicines for the treatment of cancer and related diseases and conditions.

QSAM’s initial technology is Samarium-153 DOTMP, aka CycloSam®, a clinical-staged bone targeting radiopharmaceutical from IsoTherapeutics Group, leaders in the nuclear medicine space who also developed FDA-approved and commercially available Quadramet® (Samarium-153 EDTMP), indicated for pain palliation.

CycloSam® has already demonstrated safety and efficacy in animal studies and a human trial performed at the prestigious Cleveland Clinic. This drug candidate utilizes an FDA approved radioisotope combined with a novel chelate that has demonstrated increased efficacy and decreased side effects in animal models.

Further, CycloSam® utilizes a streamlined, just-in-time manufacturing process. Given these factors, management believes there is a strong pathway to commercialization.

CycloSam® is cleared by the FDA under an investigator IND to commence human dosing immediately in patients with osteosarcoma and bone metastasis.

CycloSam® was also cleared by FDA and successfully used under a single-patient IND to perform bone marrow ablation prior to allogenic marrow transplantation (BMA/T) in 2020.

Interested investors can find out more about QSAM Biosciences, Inc. and the Company’s wholly-owned subsidiary, QSAM Therapeutics, Inc. by visiting https://qsambio.com/

______________________________________________________________________

*Nuclear Medicine Market Size Worth $12.6 Billion by 2027 | CAGR 9.5%

February 2020 | Report Format: Electronic (PDF) The global nuclear medicine market size is expected to reach USD 12.6 billion by 2027, expanding at a CAGR of 9.5%, according to a new report by Grand View Research, Inc.

Research and development of advanced technologies by the key players for diagnosis and treatment of diseases is expected to drive the radiopharmaceuticals market.

______________________________________________________________________

Disclaimer and Disclosures: MicroCap MarketPlace (MCMP) is a financial publisher and not a FINRA broker/dealer or investment adviser. MCMP is not registered with the SEC / U.S. Securities and Exchange Commission or any state securities regulatory agency. Readers, subscribers and web site visitors are responsible for individual investment decisions. All information contained in our newsletters or on our web site and in our blogs should be independently verified with the featured companies and readers should always conduct their own research and due diligence and engage professional investment advisers as they deem appropriate before making investment decisions. Please review the Terms and Conditions of Use, including without limitation all disclaimers of warranties and limitations on liability contained therein. Your use of any information on our websites, contained herein or in our newsletters and blogs constitutes your agreement of same. Officers, employees and affiliates may hold positions in the featured securities discussed in our newsletters or on our web site and blogs and may buy or sell said securities at any time without further notice. MCMP and/or affiliates may from time to time receive cash and/or equity compensation from featured companies for corporate marketing and communications services. In the interest of full disclosure, Mike Casson, MCMP’s Founder/Executive Editor is also president of Casson Communications, LLC (CCLLC) an affiliated company. CCLLC has received five thousand four hundred dollars in cash compensation from OTC Stock Review for marketing and communication services and allocated a portion of that compensation for the distribution of this article as part of said services. You should be aware of these potential conflicts of interest. We believe the information contained herein and in our publications to be reliable but cannot guarantee its accuracy; therefore, all information is provided as is without warranty of any kind. Past results are not necessarily indicative of future performance.

Posted by AIA Research & Editorial Staff
Categories: Uncategorized

Comments are closed.